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Background: Colistin is a last resort antibiotic for the treatment of carbapenem-resistant Gram negative infections.
Until recently, mechanisms of colistin resistance were limited to chromosomal mutations which confer a high
fitness cost and cannot be transferred between organisms. However, a novel plasmid-mediated colistin resistance
mechanism, encoded by the mcr-1 gene, has been identified, and has since been detected worldwide. The mcr-1
colistin resistance mechanism is a major threat due to its lack of fitness cost and ability to be transferred between
strains and species. Surveillance of colistin resistance mechanisms is critical to monitor the development and spread
of resistance.This study aimed to determine the prevalence of the plasmid-mediated colistin resistance gene, mcr-1,
in colistin-resistant E. coli and Klebsiella spp. isolates in the Western Cape of South Africa; and whether colistin resistance
is spread through clonal expansion or by acquisition of resistance by diverse strains.
Methods: Colistin resistant E. coli and Klebsiella spp. isolates were collected from the NHLS microbiology laboratory at
Tygerberg Hospital. Species identification and antibiotic susceptibility testing was done using the API® 20 E system and
the Vitek® 2 Advanced Expert System™. PCR was used to detect the plasmid-mediated mcr-1 colistin resistance gene
and REP-PCR was used for strain typing of the isolates.
Results: Nineteen colistin resistant isolates, including 12 E. coli, six K. pneumoniae and one K. oxytoca isolate,
were detected over 7 months from eight different hospitals in the Western Cape region. The mcr-1 gene was
detected in 83% of isolates which were shown to be predominantly unrelated strains.
Conclusions: The plasmid-mediated mcr-1 colistin resistance gene is responsible for the majority of colistin resistance
in clinical isolates of E. coli and Klebsiella spp. from the Western Cape of South Africa. Colistin resistance is not clonally
disseminated; the mcr-1 gene has been acquired by several unrelated strains of E. coli and K. pneumoniae. Acquisition
of mcr-1 by cephalosporin- and carbapenem-resistant Gram negative bacteria may result in untreatable infections and
increased mortality. Measures need to be implemented to control the use of colistin in health care facilities and in
agriculture to retain its antimicrobial efficacy.
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The global increase in antibiotic resistance is extremely
concerning as it compromises patient outcome and
increases the financial burden on health-care systems
[1, 2]. Amongst Gram-negative bacteria, including the
Enterobacteriaceae, the situation is particularly alarm-
ing as the available treatment options for multi-
resistant organisms are limited, and there is a paucity
of new drugs being developed. The use of β-lactam
antibiotics to treat Enterobacteriaceae has been
severely compromised by the spread of extended-
spectrum β-lactamases (ESBLs), which confer resist-
ance to third and fourth generation cephalosporins,
resulting in increased carbapenem use. The emer-
gence and spread of carbapenem resistance, primarily
mediated by the plasmid-encoded carbapenemases, is
therefore of extreme concern [3, 4].
The polymyxins, colistin and polymyxin B, are the “last
resort” antibiotics for treatment of infections with carba-
penemase producing Enterobacteriaceae and in 2012
colistin was reclassified by the WHO as critically im-
portant for human medicine [5]. Colistin is a polycatio-
nic molecule which interacts with the bacterial outer
membrane by displacing divalent cations from the
negatively-charged phosphate groups of the Lipid A of
the lipopolysaccharide membrane, resulting in cell lysis.
Traditionally, colistin resistance was considered to be
due to rare chromosomal mutations in the genes encod-
ing the PmrA/PmrB and PhoP/PhoQ two component
signalling systems or the negative regulator MgrB [6].
These mutations result in modifications to the Lipid A
molecule, or rarely, the complete loss of Lipid A. These
chromosomal mutations confer a fitness cost to the or-
ganism and are unlikely to be maintained in the absence
of colistin selection; and are not transferable to other
organisms. In November 2015, the emergence of a novel
plasmid-mediated colistin resistance mechanism was de-
scribed [7]. This colistin resistance is conferred by the
mcr-1 gene which was identified on an IncI2 plasmid,
pHNSHP45, isolated from an Escherichia coli isolate
from a pig in China. The mcr-1 gene encodes a phos-
phoethanolamine transferase enzyme which transfers a
phosphoethanolamine to Lipid A; conferring resistance
to colistin. The plasmid was shown to be transferable by
conjugation and transformation, and is stably maintained
in E. coli, Pseudomonas aeruginosa and Klebsiella pneu-
moniae for at least 14 days, in the presence or absence
of colistin [7]. Subsequent studies have identified the mcr-
1 gene in various Enterobacteriaceae, including E. coli, K.
pneumoniae and Salmonella spp., in Asia, Europe, North
America and Africa [8–16].
Plasmid-mediated colistin resistance mechanisms offer
no fitness cost and are stably maintained in the absence
of colistin selection [7]. These mechanisms can betransferred between bacterial strains and therefore pose
a massive risk to the treatment of Gram-negative infec-
tions. Distribution of these plasmids amongst carba-
penem resistant organisms, especially in the hospital
setting, may catalyse a return of the “pre-antibiotic era”
for the treatment of infections with Gram-negative bac-
terial pathogens. This study aimed to determine the
prevalence of the plasmid-mediated colistin resistance
gene, mcr-1, in colistin-resistant E. coli and Klebsiella
spp. isolates in the Western Cape of South Africa; and
to determine whether colistin resistance is spread
through clonal expansion or by acquisition of resistance
by diverse strains. Surveillance of colistin resistance
mechanisms present in a population is vital for advising
effective treatment of bacterial infections and for
monitoring the development and spread of resistance.Methods
Consecutive colistin resistant E. coli and Klebsiella spp.
isolates were collected from routinely collected clinical
specimens processed at the National Health Laboratory
Service (NHLS) laboratory at Tygerberg Hospital, as part
of convenience sampling, between January and August
2016. The NHLS Microbiology laboratory at Tygerberg
Academic Hospital receives specimens from Tygerberg
Hospital as well as a number of regional and district
hospitals. The hospital serves a drainage area of approxi-
mately half of Cape Town (predominantly the Northern
and Eastern sub-districts), as well as the West Coast,
Cape Winelands and Overberg rural districts. The hos-
pital acts as a referral centre for 4 regional hospitals, 17
district hospitals and over 120 primary health care
clinics. The population served is approximately 2.6 mil-
lion, representing just under half the population of the
Western Cape. Microbial identification was done using
the API® 20 E system (Analytical Profile Index 20 Enter-
obacteria) (bioMérieux) or the Vitek® 2 Advanced Expert
System™ (bioMérieux) and antimicrobial susceptibilities
were determined using the Vitek® 2 Advanced Expert
System™. All routinely identified colistin-resistant E. coli
and Klebsiella spp. isolates were collected for the study.
Limited specimen information, including specimen type,
date and hospital of collection was identified based on
the laboratory specimen number. These isolates were
not included in a previous study which identified
mcr-1 in South Africa [16]. Colistin minimum inhibi-
tory concentrations (MICs) were determined by gradi-
ent diffusion using colistin Etest® strips (bioMérieux).
Colistin susceptibility was interpreted using the Euro-
pean Committee on Antimicrobial Susceptibility Test-
ing (EUCAST) Clinical Breakpoints (version 6.0)
which defines resistance to colistin in Enterobacteria-
ceae as MIC >2 μg/mL [17].
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ously described, using the primers CLR5 F: 5′-CGGT
CAGTCCGTTTGTTC-3′ and CLR5 R: 5′-CTTGGTC
GGTCTGTAGGG-3′ [7]. An rpoB internal amplification
control using RpoB-F 5′-AACCAGTTCCGCGTTGG
CCTGG-3′ and RpoB-R 5′-CCTGAACAACACGCTCG
GA-3′ was included in the mcr-1 PCR [18]. PCRs were
done using the KAPA Taq ReadyMix PCR Kit (Kapa Bio-
systems) with 0.4 μM of each primer in a 25 μL reaction
volume, using an annealing temperature of 60 °C and
35 cycles. Amplicons were separated on a 2% w/v agar-
ose gel and detected using the Alliance 2.7 imaging sys-
tem (UVITec). Sanger sequencing was done to confirm
the mcr-1 amplicons.
Strain typing was done by REP-PCR using primers
REP2I: 5′-ICGICTTATCIGGCCTAC-3′ and REP1R: 5′-
IIIICGICGICATCIGGC-3′ [19]. E. coli strain ATCC
25922 and K. pneumoniae strain ATCC 700603 were
used as controls for strain typing. PCR was done essen-
tially as previously described using an annealing
temperature of 40 °C for 1 min and extension for 8 min
at 65 °C, for 30 cycles. Digitised REP-PCR gel images
were analysed using GelCompar II version 7.5 (Applied
Maths). Banding patterns were normalised to the
KAPA™ Universal Ladder (Kapa Biosystems) and band
intensity was not evaluated. Similarity between the pro-
files was calculated with the band matching Dice coeffi-
cient and dendrograms for each species were produced
by the unweighted pair group method with arithmetic
averages (UPGMA) and neighbour-joining algorithms.
Identical strains were defined as isolates with >97% simi-
larity, closely related isolates with ≥95% similarity; iso-
lates with <95% similarity were defined as unrelated
strains, based on the UPGMA dendograms [20].Results
Twenty-one colistin-resistant isolates were collected
over the 7 month period between January and August
2016, based on Vitek® 2 susceptibility testing (n = 14 E.
coli, n = 6 K. pneumoniae, n = 1 Klebsiella oxytoca)
(Table 1). These isolates were identified from specimens
collected from 19 patients from eight hospitals in the
Western Cape region; Hospital A (n = 6), Hospital B
(n = 3), Hospital C (n = 3), Hospital D (n = 2), Hospital
E (n = 2), Hospital F (n = 1), Hospital G (n = 1) and
Hospital H (n = 1) (Table 1). The majority of isolates
were obtained from urine specimens. Two E. coli
(CEC12 and CEC15) and two K. pneumoniae (CK1 and
CK7) isolates were each obtained from urine specimens
from the same patient taken at least 2 months apart. All
of the E. coli isolates, with the exception of CEC10, are
susceptible to 3rd and 4th generation cephalosporins,
while four of the six K. pneumoniae isolates are resistantto both, one of which is also resistant to carbapenems
(CK2).
There was good correlation between the Vitek and
Etest colistin susceptibility results in the E. coli isolates.
For 12 of the 14 E. coli isolates the MICs agreed, or
showed a single fold dilution difference (Table 1). The
remaining two E. coli isolates (CEC5 and CEC14)
were found to be colistin susceptible by Etest
(MIC = 0.5 μg/mL). The VITEK susceptibilities were
repeated on these isolates; and repeat testing found
the colistin MIC of both isolates to be 0.5 μg/mL;
these isolates were reclassified as colistin susceptible
and excluded from the analysis. One K. pneumoniae
isolate, CK6, was lost during subsequent culture and
was excluded from further analysis. The correlation
between the Vitek and Etest susceptibility results was
poor for the Klebsiella spp. isolates; with all but one
isolate showing a greater than 1 fold dilution differ-
ence between the two testing methods. Therefore, we
found 19 colistin resistant isolates (12 E. coli, 6 K.
pneumonia, and 1 K. oxytoca).
The mcr-1 gene was detected in 15 out of 18 (83%)
confirmed colistin-resistant isolates, including 10/12 E.
coli isolates and 5/6 Klebsiella spp. isolates (Table 1). As
no mcr-1 positive control strain was available, selected
mcr-1 amplicons from both E. coli and Klebsiella spp.
isolates were sequenced and shown to share 100% iden-
tity with the published mcr-1 gene sequence (Genbank
accession number: NG_050417.1) [7]. Four mcr-1 posi-
tive Klebsiella isolates were reported to be colistin sus-
ceptible by the Etest method. The two mcr-1-negative
colistin resistant E. coli isolates (CEC12 and CEC15),
were isolated from the same patient.
Strain typing using REP-PCR identified 11 unrelated
strain types amongst the E. coli and 4 amongst the Kleb-
siella spp. isolates (Fig. 1). Two genetically related E. coli
isolates (CEC12 and CEC15), with 95% similarity, and
two identical K. pneumoniae isolates (CK1 and CK7)
were respectively identified from the same patient. Iso-
late CK1 was mcr-1-positive, while CK7 was mcr-1-nega-
tive, even after repeating the PCR. Both isolates were
however colistin resistant, although CK7 had a higher
colistin MIC (16 μg/mL) than CK1 (4 μg/mL).
Discussion
The plasmid-mediated mcr-1 colistin resistance gene
was found to be the predominant colistin resistance
mechanism amongst E. coli and Klebsiella spp. clinical
isolates in the Western Cape of South Africa, present in
83% of colistin resistant isolates. These mcr-1 positive
isolates were obtained from seven hospitals across the
Western Cape, indicating that this resistance mechanism
is widespread in the province. Previously, mcr-1 has
been reported in eight colistin resistant E. coli isolates
Table 1 Specimen details, colistin susceptibilities and presence of mcr-1 in colistin resistant isolates
Species Isolate Specimen
type
Date of collection Hospital Vitek MIC (μg/ml) Etest MIC (μg/ml) mcr-1 PCR Additional antibiotic resistance
E. coli CEC1 Urine 25/01/2016 A 4 (R) 4 (R) + SXT,
CEC2 Urine 16/01/2016 F 4 (R) 4 (R) + SXT, CIP, CXM(I)
CEC3 Urine 15/01/2016 D 16 (R) 4 (R) + none
CEC4 Urine 16/01/2016 E 8 (R) 4 (R) + SXT, AMP, CXM(I)




27/01/2016 D 8 (R) 4 (R) + SXT, AMP, AMC(I), CIP, CXM(I),
TZP(I)
CEC8 Urine 12/02/2016 A 8 (R) 4 (R) + SXT, AMP, CIP
CEC9 Urine 16/02/2016 B 4 (R) 2 (S) + SXT, AMP, CIP
CEC10 Urine 16/02/2016 C 4 (R) 2 (S) + AMP, AMC(I), CIP, CXM, CTX,
CAZ, FEP, AMI(I), TZP(I)
CEC11 Urine 03/03/2016 B 8 (R) 4 (R) + SXT, AMP,
CEC12a Urine 23/05/2016 A 4 (R) 4 (R) - SXT, AMP, AMC(I)
CEC13 Urine 10/06/2016 G 4 (R) 4 (R) + SXT, AMP, CIP, CXM(I), FOX(I)
CEC14 Urine 27/07/2016 A 4 (R)c 0.5 (S) - none
CEC15a Urine 23/07/2016 A 4 (R) 4 (R) - SXT, AMP
K.
pneumoniae
CK1b Urine 20/05/2016 E 4 (R) 2 (S) + AMP, AMC, CIP, CXM, CTX, CAZ,
FEP, TZP(I)
CK2 Sputum 17/06/2016 A 16 (R) 4 (R) + SXT, AMP, AMC, CIP, CXM, FOX,
CTX, CAZ, FEP, GEN, AMI, TZP,
ETP, IPM, MEM
CK5 Urine 17/07/2016 C 4 (R) 0.5 (S) + AMP, CXM
CK6 Urine 26/07/2016 A 16 (R) Isolate lost during culture SXT, AMP, AMC, CIP, CXM, FOX,
CTX, CAZ, FEP, GEN, AMI(I), TZP
CK7b Urine 12/08/2016 E 16 (R) 4 (R) - SXT, AMP, AMC, CIP, CXM, CTX,
CAZ, FEP, GEN, TZP(I)
CK8 Sputum 02/07/2016 C 4 (R) 0.5 (S) + AMP, GEN(I), AMI(I)
K. oxytoca CK3 Superficial
skin swab
21/06/2016 B 16 (R) 0.25 (S) + AMP
aSuccessive E. coli isolates obtained from the same patient. bSuccessive K. pneumonia isolates obtained from the same patient. cRepeat Vitek susceptibility testing
redefined the colistin MIC as 0.5 μg/mL; both these isolates were excluded from further analysis. R resistant, I intermediate, S susceptible, SXT trimethoprim-
sulfamethoxazole, CIP ciprofloxacin, CXM cefuroxime, AMP ampicillin, AMI amikacin, AMC amoxicillin-clavulanic acid, TZP piperacillin-tazobactam, CTX cefotaxime/
ceftriaxone, CAZ ceftazidime, FEP cefepime, GEN gentamicin, ETP ertapenem. IPM imipenem, MEM meropenem
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from Cape Town [16]; however the presence of mcr-1
in clinical Klebsiella isolates has not been previously
described in South Africa. This highlights the need
for screening for mcr-1 in other Gram negative
organisms in addition to E. coli. The presence of the
mcr-1 colistin resistance mechanism in K. pneumoniae
is particularly concerning in light of the high prevalence
of ESBL-production as well as ongoing emergence of
carbapenem resistance amongst K. pneumoniae in
South Africa [21, 22]. The mcr-1 gene was detected
in two K. pneumoniae isolates which are resistant to
3rd and 4th generation cephalosporins, one of which
is also resistant to carbapenems, indicating that these
highly resistant organisms are already present in our
population.The mcr-1 gene was detected in diverse strains of E.
coli and K. pneumoniae from geographically diverse hos-
pitals, indicating that this plasmid-mediated colistin re-
sistance mechanism is not distributed clonally, but
mediated by multiple independent acquisitions of
mcr-1 containing plasmids. Six of these hospitals are
regional or district hospitals, where colistin use is ex-
tremely uncommon, and it is probable that these iso-
lates are present in the community, rather than
arising as a result of selective pressure in hospitals.
This is consistent with previous data from South Africa
which showed that the mcr-1 positive E. coli isolates from
Johannesburg and Pretoria were unrelated strains, con-
taining mcr-1 on 3 different plasmid types [23]. Plasmid
typing has not yet been done on the isolates in this study,

















































Fig. 1 UPGMA dendograms representing the relatedness of a E. coli and b Klebsiella pneumoniae strains. Clustering was consistent between the
UPGMA and neighbor-joining dendograms (data not shown)
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single mcr-1 containing plasmid amongst different strains
and species, or whether mcr-1 is present on multiple plas-
mid types in this community.
The two genetically identical K. pneumoniae isolates,
obtained from the same patient, appear to have distinct
colistin resistance mechanisms. The first isolate con-
tained the mcr-1 gene, while the second was mcr-1-
negative. Further studies are required to explain this
finding, which may be due to loss of the mcr-1 plasmid
in combination with development of chromosomal colis-
tin resistance mutations, or acquisition of an alternative
plasmid-mediated gene such as mcr-2 [24]. New muta-
tions in mcr-1, resulting in increased colistin MICs and
loss of one or both primer binding sites, is another specu-
lative explanation. Both of these isolates are resistant to
3rd and 4th generation cephalosporins and the second iso-
late had also acquired resistance to trimethoprim-
sulfamethoxazole and gentamicin, which may be linked to
acquisition of additional plasmids. The mechanism/s of
colistin resistance in the other mcr-1 negative isolates also
requires further investigation.
The high prevalence of the mcr-1 colistin-resistance
gene in China was attributed to the widespread use of
colistin in their veterinary sector [7]. In South Africa,
an increased prevalence of colistin resistance was ob-
served in E. coli obtained from chickens in the last
quarter of 2015, as part of the MIC surveillance pro-
gram, and 79% of these colistin resistant E. coli isolates
(19/24) were mcr-1 positive [25]. As a result of thesefindings, as well as the presence of mcr-1 in human
isolates in South Africa, and colistin’s position as an
antibiotic of last resort for human health, the South
African Veterinary Council (SAVC) recently recom-
mended that colistin not be used in feed producing ani-
mals unless its use can be justified by a sensitivity test
showing that it is the only therapeutic option available
[25]. Prudent use of colistin in agriculture is vital to
prevent further spread of the mcr-1 gene to other
bacteria and to retain its use in humans and animals
[25, 26].
In July 2016, EUCAST issued a statement recom-
mending that the Etest not be used for colistin MIC
determination, after evaluating its use on a collection of
isolates with and without known colistin resistance
mechanisms [27]. Results indicated that the Etest under-
estimates MIC values. Furthermore, In the December
2016 issue of the CLSI AST News Update, the Clinical
Laboratory Standards Institute (CLSI)/EUCAST Joint
Working Group recommended that broth microdilu-
tion, without surfactant, be used as the reference
method for testing colistin and that disk and agar
gradient diffusion methods not be used as they yield
unacceptably high error rates [28]. This is consistent
with the findings in this study, which found that Etest
MICs were typically lower than those of the Vitek, al-
though considerably more so for Klebsiella spp. in
which the Etest MICs in 5 of the 6 isolates were at
least 2 dilutions lower, even in the presence of the
mcr-1 resistance gene.
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antibiotic susceptibility profiles. The E. coli isolates were
all susceptible to carbapenems, and only one isolate was
resistant to cephalosporins and six to the fluoroquino-
lone ciprofloxacin. However, four of the six K. pneumo-
niae isolates were resistant to 3rd and 4th fourth
generation cephalosporins, one of which was also resistant
to carbapenems. Other studies have also detected the
mcr-1 resistance gene in isolates which harbour plasmid-
mediated ESBL and carbapenemase genes [29–32], and
notably, mcr-1 was found to be present on the same plas-
mid as an ESBL gene in an E. coli isolate in France [33].
This highlights the threat of widespread dispersion of this
resistance mechanism and its introduction into more re-
sistant strains. New antibiotics are unlikely to solve the
antibiotic resistance problem in the near future, and
surveillance of colistin resistance and the prudent use
of colistin in humans and animals are vital to retain
colistin activity.
Conclusions
The plasmid-encoded mcr-1 gene is the predominant co-
listin resistance mechanism in E. coli and Klebsiella spp.
isolates from clinical specimens in the Western Cape of
South Africa. The mcr-1 gene was detected in unrelated
strains from patients at various hospitals throughout the
province, suggesting that the mcr-1 gene has been
acquired by multiple strains and is not clonally spread.
The presence of mcr-1 in both E. coli and K. pneumo-
niae isolates is of concern; the presence of mcr-1 in iso-
lates resistant to 3rd and 4th generation cephalosporins
and carbapenems is alarming, and highlights the threat
of potentially untreatable infections. Increased surveil-
lance of colistin resistance mechanisms to monitor their
acquisition and spread is vital, and ongoing efforts to en-
sure the judicious use of colistin (and indeed all antibi-
otics) both in agriculture and in health-care facilities are
welcomed.
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